Researchers Identify miR-342-E2F Switch in TNBC, Cutting Metastatic Outgrowth in Preclinical Models
Updated
Updated · Inside Precision Medicine · Aug 21
Researchers Identify miR-342-E2F Switch in TNBC, Cutting Metastatic Outgrowth in Preclinical Models
2 articles · Updated · Inside Precision Medicine · Aug 21
Summary
Low miR-342 and high E2F activity marked triple-negative breast cancer cells with greater metastatic capacity, identifying a potentially targetable program behind disease spread rather than primary-tumor growth.
Preclinical mouse and human TNBC models showed that restoring miR-342 or blocking the pathway with CDK4/6 inhibitor palbociclib reduced metastatic outgrowth, especially after cancer cells had already seeded distant organs.
Multi-omics analysis linked miR-342 loss to overactive E2F signaling, suggesting dormant disseminated cells can be pushed into dangerous secondary tumors when that pathway is unchecked.
The findings point to biomarker-selected use of palbociclib in a TNBC subgroup with low miR-342 and high E2F activity, instead of broad use across this molecularly diverse cancer.
The study remains preclinical, with next steps including validation in patient-derived models and eventual trials that account for RB status, E2F activity, miR-342 levels and resistance mechanisms.